NVMM Guideline

Laboratory detection of highly resistant microorganisms (HRMO)

Authors
Dr. A.T. Bernards, clinical microbiologist
Prof. dr. M.J.M. Bonten, clinical microbiologist
Dr. J. Cohen Stuart, clinical microbiologist
Dr. B. Diederen, clinical microbiologist
Dr. W.H.F. Goessens, medical microbiologist
Prof. dr. H. Grundmann, clinical microbiologist
Prof. dr. J.A.J.W. Kluytmans, clinical microbiologist
Drs. M.F.Q. Kluytmans - van den Bergh, epidemiologist
Dr. M.A. Leverstein - van Hall, clinical microbiologist
Dr. J.W. Mouton, clinical microbiologist
Dr. N. al Naiemi, clinical microbiologist
Dr. A. Troelstra, clinical microbiologist
Prof. dr. C.M.J.E. Vandenbroucke - Grauls, clinical microbiologist
Dr. M.C. Vos, clinical microbiologist
Prof. dr. A. Voss, clinical microbiologist

Version
1.0

Date of adoption by general assembly of the NVMM
November 17th, 2011

Revision
2016
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Chapter 1 - General introduction</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Background</td>
<td>5</td>
</tr>
<tr>
<td>1.2 Objective</td>
<td>5</td>
</tr>
<tr>
<td>1.3 Target group</td>
<td>5</td>
</tr>
<tr>
<td>1.4 Realisation</td>
<td>5</td>
</tr>
<tr>
<td>1.5 Working group</td>
<td>6</td>
</tr>
<tr>
<td>1.6 Topics</td>
<td>7</td>
</tr>
<tr>
<td>1.7 Methods</td>
<td>7</td>
</tr>
<tr>
<td>1.8 Authorisation and implementation</td>
<td>8</td>
</tr>
<tr>
<td>1.9 Revision</td>
<td>9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 2 - <em>Staphylococcus aureus</em></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Methicillin resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 3 - <em>Streptococcus pneumoniae</em></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Penicillin(group) resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
<tr>
<td>3.2 Vancomycin resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 4 - <em>Enterococcus faecium</em></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Penicillin(group) resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
<tr>
<td>4.2 Vancomycin resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 5 - <em>Enterobacteriaceae</em></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1 Extended-spectrum beta-lactamases</td>
<td>10</td>
</tr>
<tr>
<td>5.2 Plasmid-mediated AmpC beta-lactamases</td>
<td>[in preparation]</td>
</tr>
<tr>
<td>5.3 Carbapenemases</td>
<td>21</td>
</tr>
<tr>
<td>5.4 Quinolone resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
<tr>
<td>5.5 Aminoglycoside resistance</td>
<td></td>
</tr>
<tr>
<td>[in preparation]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chapter 6 - Non-fermenting gram-negative bacteria (<em>Acinetobacter</em> spp. / <em>Pseudomonas aeruginosa</em> / <em>Stenotrophomonas maltophilia</em>)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1 Ceftazidime- and/or piperacillin resistance: acquired beta-lactamases (<em>Acinetobacter</em> spp. / <em>P. aeruginosa</em>) [in preparation]</td>
<td></td>
</tr>
<tr>
<td>6.2 Carbapenemases (<em>Acinetobacter</em> spp. / <em>P. aeruginosa</em>) [in preparation]</td>
<td></td>
</tr>
<tr>
<td>6.3 Quinolone resistance (<em>Acinetobacter</em> spp. / <em>P. aeruginosa</em>) [in preparation]</td>
<td></td>
</tr>
<tr>
<td>6.4 Aminoglycoside resistance (<em>Acinetobacter</em> spp. / <em>P. aeruginosa</em>) [in preparation]</td>
<td></td>
</tr>
<tr>
<td>6.5 Co-trimoxazole resistance (<em>S. maltophilia</em>) [in preparation]</td>
<td></td>
</tr>
</tbody>
</table>
CHAPTER 1 - GENERAL INTRODUCTION

1.1 Background
Antimicrobial resistance is rapidly emerging worldwide, and affects both healthcare and community settings, and intensive livestock agriculture [EARSS 2008, SWAB 2010, VANTURES 2008]. The increase in antimicrobial resistance concerns not only the number of individuals infected or colonised with antimicrobial resistant microorganisms, but also the diversity of underlying resistance mechanisms [Paterson 2005, Queenan 2007]. Antimicrobial resistance hampers the options for antimicrobial therapy, and results in increased morbidity, mortality and healthcare costs [Carmeli 2002, Cosgrove 2005, Mauldin 2010].

National guidelines for the control of highly resistant microorganisms (HRMO) have been developed by the Dutch Workingparty on Infection Prevention (WIP). [Kluytmans 2005, WIP 2005, WIP 2007] HRMO are defined as microorganisms that 1) are known to cause disease; 2) have acquired an antimicrobial resistance pattern that hampers (empirical) therapy, and 3) have the potential to spread in healthcare facilities if – in addition to standard precautions – no transmission-based precautions are taken.

The efficient control of HRMO strongly depends on the adequate laboratory detection of antimicrobial resistance [Metan 2005]. The implementation of rapid and accurate laboratory detection methods may improve the timely initiation of appropriate antimicrobial therapy as well as infection control measures to prevent the spread of antimicrobial resistant microorganisms within healthcare facilities. Furthermore, it may decrease the duration of preemptive isolation precautions [Wassenberg 2010], and prevent the inappropriate institution of contact tracing.

1.2 Objective
This guideline provides recommendations on the appropriate use of currently available diagnostic laboratory methods for the timely and accurate detection of HRMO, as defined by the WIP [Kluytmans 2005, WIP 2005], in patients and healthcare workers. Herewith, it aims to standardise and improve the diagnostic laboratory procedures that are used for the detection of HRMO in Dutch medical microbiology laboratories.

1.3 Target group
This guideline is aimed at clinical microbiologists, infection control practitioners, laboratory technicians and medical microbiology laboratories that are responsible for the detection of HRMO in patients and healthcare workers in the Netherlands.

1.4 Realisation
The development of this guideline was initiated by the Netherlands Society for Medical Microbiology (NVMM) in 2009, and funded by the Stichting Kwaliteitsgelden Medisch Specialisten (SKMS).
1.5 Working group

This guideline has been developed by a working group that was instituted by the NVMM in 2010. The working group consists of clinical microbiologists, and medical microbiologists with known expertise in the field of the laboratory detection of antimicrobial resistance. The working group members represent both university and non-university centres from different regions of the Netherlands. The working group members are jointly responsible for the full text of this guideline.

1.5.1 Working group members

The following persons participated in the development of the guideline:

- Dr. A.T. Bernards, clinical microbiologist (LUMC, Leiden)
- Prof. dr. M.J.M. Bonten, clinical microbiologist (UMC Utrecht)
- Dr. J. Cohen Stuart, clinical microbiologist (UMC Utrecht, Utrecht)
- Dr. B. Diederen, clinical microbiologist (Regional Laboratory of Public Health Haarlem, Haarlem)
- Dr. W.H.F. Goessens, medical microbiologist (Erasmus MC, Rotterdam)
- Prof. dr. H. Grundmann, clinical microbiologist (UMC Groningen, Groningen)
- Prof. dr. J.A.J.W. Kluytmans, clinical microbiologist (Amphia Hospital, Breda / St.Elisabeth Hospital, Tilburg / TweeSteden Hospital, Tilburg / VUmc, Amsterdam)\(^1\)
- Drs. M.F.Q. Kluytmans - van den Bergh, epidemiologist (Amphia Academy Infectious Disease Foundation, Breda)\(^2\)
- Dr. M.A. Leverstein - van Hall, clinical microbiologist (UMC Utrecht, Utrecht / RIVM, Bilthoven)
- Dr. J.W. Mouton, clinical microbiologist (Canisius-Wilhelmina Hospital, Nijmegen / UMC St. Radboud, Nijmegen)
- Dr. N. al Naiemi, clinical microbiologist (Regional Public Health Laboratory, Enschede)
- Dr. A. Troelstra, clinical microbiologist (UMC Utrecht, Utrecht)
- Prof. dr. C.M.J.E. Vandenbroucke–Grauls, clinical microbiologist (VUmc, Amsterdam)
- Dr. M.C. Voss, clinical microbiologist (Erasmus MC, Rotterdam)\(^1\)
- Prof. dr. A. Voss, clinical microbiologist (Canisius-Wilhelmina Hospital, Nijmegen / UMC St. Radboud, Nijmegen)

\(^1\) Chairman
\(^2\) Secretary

1.5.2 Conflict of interest

No potential conflict of interest disclosed

Dr. A. T. Bernards
Prof. dr. M.J.M. Bonten
Dr. B. Diederen
Dr. W.H.F. Goessens
Prof. dr. H. Grundmann
Drs. M.F.Q. Kluytmans – van den Bergh
Dr. J.W. Mouton

2011.11.17, version 1.0
1.6 Topics

1.6.1 Highly resistant microorganisms (HRMO)

In accordance with the definitions of HRMO issued by the WIP [Kluymans 2005, WIP 2005] this guideline provides recommendations on the following combinations of microorganism, susceptibility pattern and/or resistance mechanisms: 1) *Staphylococcus aureus*: methicillin resistance; 2) *Streptococcus pneumoniae*: penicillin(group) resistance and vancomycin resistance; 3) *Enterococcus faecium*: penicillin(group) resistance and vancomycin resistance; 4) *Enterobacteriaceae*: extended-spectrum beta-lactamases, plasmid-mediated AmpC beta-lactamases, carbapenemases, quinolone resistance, and aminoglycoside resistance; 5) non-fermenting gram-negative bacteria (*Acinetobacter* spp., *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*): ceftazidime- and piperacillin resistance (acquired beta-lactamases), quinolone resistance, aminoglycoside resistance, carbapenemases, and co-trimoxazole resistance.

1.6.2 Aspects of laboratory detection

This guideline provides recommendations on the laboratory detection of HRMO. For recommendations on measures to prevent transmission of HRMO the working group refers to the relevant guideline of the WIP [WIP 2005]. Several aspects of the laboratory detection of HRMO are covered in this guideline, i.e. 1) detection of carriage: culture sites, number of cultures, culture materials and transport; 2) laboratory methods: direct molecular detection, solid agar media, broth enrichment, identification and susceptibility testing (including screening, phenotypic and genotypic confirmation, and quality control); 3) contact tracing: adjusting diagnostic methods in case of a ‘known’ strain and (molecular) typing; and 4) reporting: laboratory- and patient information system.

1.6.3 Surveillance of resistance

Although the surveillance of antimicrobial resistance is not part of this guideline on the laboratory detection of HRMO, the working group does recommend medical microbiology laboratories to
participate in national surveillance programs that aim on the monitoring and early detection of trends in antimicrobial resistance on a national level.

1.7 Methods

1.7.1 Previous guidelines
This guideline replaces the previous guidelines of the NVMM on the detection of methicillin-resistant *Staphylococcus aureus* (MRSA) and extended-spectrum beta-lactamases (ESBL) in Enterobacteriaceae [NVMM 2002, NVMM 2008]. Based on current knowledge the working group judged whether previous recommendations were still up to date and applicable to the Dutch situation. If appropriate, recommendations were revised or new recommendations were added.

1.7.2 Procedures working group
The current version of the guideline has been developed during a period of eighteen months. Working group members systematically searched relevant literature and judged the quality and content of the retrieved publications. Subsequently, the working group members wrote chapters or paragraphs of the guideline, assimilating the judged literature. The text of the guideline was discussed during meetings of the working group, and adjusted accordingly.

1.7.3 Method for guideline development
This guideline has been developed in accordance with the protocol ‘Protocol voor de ontwikkeling, autorisatie en revisie van beroepsgebonden richtlijnen van de Nederlandse Vereniging voor Medische Microbiologie’ that was issued by the NVMM in 2011 [NVMM 2011]. The recommendations in this guideline are, as much as possible, based on scientific insights from published studies, where both therapeutic and infection control aspects have been taken into account. If no data were available in the literature recommendations are based on expert opinion. In the event that recommendations are based on unpublished data, the specific data are provided in Appendix C. The recommendations in this guideline are in accordance with the expert rules in antimicrobial susceptibility testing and the clinical breakpoints set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [EUCAST 2008, EUCAST 2011].

1.8 Authorisation and implementation
The final draft guideline will be provided to the NVMM for preconditional testing by it’s Quality Committee, and subsequent comment by the users of the guideline. The working group will assimilate the comment provided by the users. The details of the comment round will be provided in Appendix D. The final guideline will be provided to the assembly of the NVMM for authorisation. After authorisation the guideline will be distributed to all Dutch medical microbiology laboratories and clinical microbiologists. It will be published on the website and in the scientific journal of the NVMM.
1.9 Revision

Although this guideline reflects, as much as possible, the current knowledge on antimicrobial resistance, regular updating will remain necessary due to the ongoing technological developments and the emergence of new antimicrobial resistance mechanisms.

The working group is primarily responsible for the actuality of this guideline. By 2016, or earlier if deemed necessary, the working group will decide whether this guideline is still up to date or needs revision.
CHAPTER 5 - ENTEROBACTERIACEAE

5.1 Extended-spectrum beta-lactamases

*Dr. J. Cohen Stuart, Dr. M.A. Leverstein – van Hall, Dr. N. al Naiemi*

5.1.1 Introduction

Extended-spectrum beta-lactamases (ESBLs) are defined as plasmid-encoded enzymes that are able to hydrolyze penicillins, oxyimino-cephalosporins of the 1st, 2nd and 3rd generation, and aztreonam [Paterson 2005]. ESBLs are not active against cephamycins and carbapenems, and are usually inhibited by beta-lactamase inhibitors such as clavulanic acid [Bradford 2001]. The most prevalent ESBLs belong to class A (TEM, SHV, CTX-M) [Paterson 2005]. The inhibitor-resistant class D (OXA) ESBLs are less prevalent [Naas 2008]. Occasionally other classes of ESBLs are detected [Lahey Clinic 2011]. The recent increase in the occurrence of ESBLs is largely due to the proliferation of CTX-M beta-lactamases [Livermore 2007, al Naiemi 2006, Paterson 2005]. The presence of AmpC beta-lactamases may interfere with the detection of ESBL [Paterson 2005, Stürenburg 2004]. Therefore, laboratory methods for the detection of ESBL will be discussed separately for those species in which inducible or derepressed chromosomal AmpC beta-lactamases are uncommon or absent (group I) and those for which the presence of inducible chromosomal AmpC beta-lactamases is more rule than exception (group II) (Table 1). It is important to note that AmpC beta-lactamases are increasingly found on plasmids that are species independent, and occur in both group I and group II Enterobacteriaceae [Navarro 2001, Voets 2011, Woodford 2007].

<table>
<thead>
<tr>
<th>Table 1. Classification of Enterobacteriaceae according to the presence of chromosomal AmpC beta-lactamases</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group I</strong></td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
</tr>
<tr>
<td><em>Klebsiella spp.</em></td>
</tr>
<tr>
<td><em>Proteus mirabilis</em></td>
</tr>
<tr>
<td><em>Salmonella spp.</em></td>
</tr>
<tr>
<td><em>Shigella spp.</em></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

1 Group I: Chromosomal AmpC beta-lactamases uncommon or absent
2 Group II: Chromosomal AmpC beta-lactamases common

5.1.2 Detection of carriage

5.1.2.1 Culture sites

Feces or a rectal swab (visually contaminated) are the preferred specimens for the detection of carriage with highly resistant Enterobacteriaceae (HRE) [Paniagua 2010]. A perianal swab is slightly less sensitive, but is considered an acceptable non-invasive alternative to a rectal swab [Lautenbach 2005, Wiener-Well 2010]. A perineal swab is not recommended.
Dependent on the clinical signs and age the following additional sites should be sampled:

- Productive cough
- Intubation
- Wound
- Intubation - sputum or aspirate
- Wound - wound swab
- Indwelling urinary catheter
- Neonate
- Throat swab

5.1.2.2 Number of cultures
A single set of cultures is considered sufficient for the targeted screening for carriage of HRE. Although repeated sampling may decrease the sample error, scientific data on this issue are currently insufficient to justify a recommendation to perform duplicate or repeated cultures.

Once a patient has been identified as a carrier of HRE, it is not clear how many culture sets have to be taken to reliably identify loss of carriage of HRE. Therefore, the working group has decided to follow the current recommendations for the detection of carriage of *Salmonella* spp. [Behravesh 2008], i.e. patients can be considered to be no longer carrying HRE if two culture sets, collected at least 24 hours apart, and at least 48 hours after discontinuation of antibiotic therapy are negative. Since carriage of HRE may be prolonged, in particular in patients that are hospitalised and use antibiotics [Hart 1982, Yagci 2009], the working group takes the view that it is not appropriate to take such follow-up cultures during hospitalisation.

5.1.2.3 Culture materials and transport
Swabs should be collected in an adequate transport medium that maintains the viability of the microorganisms without permitting rapid multiplication during transport. Stuart transport medium or Amies transport medium are recommended. The use of dry swabs is not recommended, as this is associated with a reduced yield [Moore 2007]. Specimens should be processed within 24 hours after sampling, and kept at 4-8°C until processing.

5.1.3 Laboratory methods
5.1.3.1 Direct molecular detection
Standardised methods for the direct molecular detection of ESBL-producing Enterobacteriaceae (ESBL-E) in clinical samples are currently not available for routine use in medical microbiology laboratories.

5.1.3.2 Solid agar media
Conventional media
The detection of ESBL-E from clinical specimens with non-selective conventional media may be hampered by overgrowth or the presence of populations with mixed susceptibilities.
**ESBL screening agar**

For targeted ESBL-E screening of clinical specimens it is recommended to use an ESBL-E screening agar, as it allows for rapid detection and isolation of ESBL-E. Three screening agars with good performance have been described in the literature: a selective agar, EbSA (Cepheid), and two chromogenic agars, chromID ESBL (bioMérieux) and Brilliance ESBL (Oxoid) [Huang 2010, Overdevest 2011]. All three screening agars can be used with no major preference. However, for group II Enterobacteriaceae the EbSA agar has been shown to have a higher specificity than the chromID ESBL [Overdevest 2011].

5.1.3.3 Broth enrichment

To our knowledge only three studies are currently available that have evaluated the use of broth enrichment in the detection of ESBL-E. Although all three studies were relatively small and used different broth enrichment media, they all reported a higher yield when broth enrichment was used. One study reported a statistically significant better performance in spiked samples as well as in clinical samples [Murk 2009]. Two other studies both found a higher yield, although not statistically significant. [Diederen unpublished data, Kluytmans unpublished data]. At this point the working group takes the view that there is insufficient evidence to provide a firm recommendation on the use of broth enrichment for the detection of ESBL-E.

5.1.3.4 Identification

Current routine identification methods for Enterobacteriaceae should be used, as there are no indications that the identification of Enterobacteriaceae is different for susceptible or resistant isolates.

5.1.3.5 Susceptibility testing

The recommended strategy for the detection of ESBL in Enterobacteriaceae is a two-step procedure, and consists of a screening step followed by a confirmation step (Figure 1). The screening step is based on the reduced susceptibility of ESBL-producing isolates to indicator cephalosporins compared with isolates that belong to the wild type population. The confirmation step is based on the in vitro inhibition of ESBL activity by the addition of clavulanic acid (phenotypic confirmation) or the detection of ESBL resistance genes (genotypic confirmation). Screening alone is insufficient to reliably detect the presence of ESBL.
Figure 1. Algorithm for the detection of extended-spectrum beta-lactamases (ESBL) in Enterobacteriaceae

SPECIES IDENTIFICATION

Group I Enterobacteriaceae (see Table 1)

Group II Enterobacteriaceae (see Table 1)

ESBL SCREENING (see Table 2)

MIC cefotaxime (or ceftriaxone) and/or ceftazidime > 1 mg/L

Negative

Positive

No ESBL

ESBL CONFIRMATION (see Table 3)

cefotaxime and ceftazidime +/- clavulanic acid

Negative

Positive

Indeterminate

No ESBL 1

ESBL 2

ESBL SCREENING (see Table 2)

MIC cefotaxime (or ceftriaxone) and/or ceftazidime > 1 mg/L

Negative

Positive 1

No ESBL

ESBL CONFIRMATION (see Table 3)

ceftazidime +/- clavulanic acid

Negative

Positive

Indeterminate

No ESBL 1

ESBL 2

1 Derepressed chromosomosomal AmpC beta-lactamase gene may result in false-positive result.
2 If cefoxitin MIC ≥ 16 mg/L, than ESBL confirmation should additionally be performed with cefepime as indicator cephalosporin.
3 Inhibitor-resistant class D (OXA) ESBL can not be excluded.
4 Hyperproduction of K1 beta-lactamase in Klebsiella oxytoca may result in a false-positive result. A positive test result for ceftazidime is indicative of ESBL production.

Screening

A. Screening in group I Enterobacteriaceae

The recommended methods for ESBL screening in group I Enterobacteriaceae are broth dilution, agar dilution, disk diffusion or an automated systems, such as VITEK 2 (bioMérieux) or Phoenix (Becton-Dickinson) (Table 2) [CLSI 2011, Drieux 2008, Paterson 2005]. It is recommended to use both cefotaxime (or ceftriaxone) and ceftazidime as indicator cephalosporins, as the MICs for cefotaxime (or ceftriaxone) and ceftazidime may differ for different types of ESBL [Biedenbach 2006, Hirakata 2005, Hope 2007, Kim 2004]. The use of cefpodoxime as indicator cephalosporin is not recommended. Although it is the most sensitive indicator cephalosporin to be used alone, it is less specific than the combination of cefotaxime (or ceftriaxone) and ceftazidime [Hope 2007]. For automated systems the combination of indicator cephalosporins for ESBL screening is dependent on the choice of the manufacturer, but should be in accordance with the recommendations on indicator cephalosporins provided in this guideline.

A screening breakpoint of > 1 mg/L is recommended for both cefotaxime (or ceftriaxone) and ceftazidime, in accordance with the guidelines issued by EUCAST and CLSI (Table 2) [CLSI 2001, EUCAST 2011]. The screening breakpoints have been set to detect isolates with an MIC above the MIC distribution of the wild-type population. The recommended screening breakpoints correspond with
the EUCAST clinical breakpoints for ‘susceptible’ Enterobacteriaceae (S: MIC ≤ 1 mg/L) [EUCAST 2011], but are lower than the clinical breakpoint of the CLSI for ceftazidime (S: MIC ≤ 4) [CLSI 2011]. Corresponding zone diameters of indicator cephalosporins are shown in Table 2.

Table 2. ESBL screening methods for Enterobacteriaceae

<table>
<thead>
<tr>
<th>Method</th>
<th>Antibiotic</th>
<th>Disk/tablet load</th>
<th>Screening positive if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Broth dilution</td>
<td>cefotaxime</td>
<td>MIC &gt; 1 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ceftazidime</td>
<td>MIC &gt; 1 mg/L</td>
<td></td>
</tr>
<tr>
<td>Agar dilution</td>
<td>cefotaxime</td>
<td>MIC &gt; 1 mg/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ceftazidime</td>
<td>MIC &gt; 1 mg/L</td>
<td></td>
</tr>
<tr>
<td>Disk diffusion</td>
<td>cefotaxime</td>
<td>30 ug</td>
<td>Inhibition zone &lt; 28 mm</td>
</tr>
<tr>
<td></td>
<td>cefotaxime</td>
<td>5 ug</td>
<td>Inhibition zone &lt; 21 mm</td>
</tr>
<tr>
<td></td>
<td>ceftriaxone</td>
<td>30 ug</td>
<td>Inhibition zone &lt; 23 mm</td>
</tr>
<tr>
<td></td>
<td>ceftazidime</td>
<td>30 ug</td>
<td>Inhibition zone &lt; 23 mm</td>
</tr>
<tr>
<td></td>
<td>ceftazidime</td>
<td>10 ug</td>
<td>Inhibition zone &lt; 22 mm</td>
</tr>
<tr>
<td>Automated systems</td>
<td>cefotaxime</td>
<td>n.a.</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
<tr>
<td></td>
<td>ceftazidime</td>
<td>n.a.</td>
<td>MIC &gt; 1 mg/L</td>
</tr>
</tbody>
</table>

MIC = minimal inhibitory concentration; n.a. = not applicable

B. Screening in group II Enterobacteriaceae

No recommendations on ESBL screening for group II Enterobacteriaceae are available in the international guidelines of the CLSI, the Health Protection Agency – British Society for Antimicrobial Chemotherapy (HPA-BSAC) or the Swedish Reference Group for Antibiotics (SRGA). For group II Enterobacteriaceae it is recommended to perform ESBL screening according to the methods described above for group I Enterobacteriaceae (Figure 1 and Table 2) [Paterson 2005]. However, the results of this screening will frequently be false-positive, due to derepression of the chromosomal AmpC gene in these species.

The use of VITEK 2 cefepime MICs is not recommended for ESBL screening in group II Enterobacteriaceae, as the sensitivity is only 54% [Cohen Stuart 2011]. Compared to screening based on MICs of cefotaxime and ceftazidime, the use of VITEK 2 Advanced Expert System (AES) ESBL alarm (bioMérieux) has been reported to increase the specificity of ESBL screening in group II Enterobacteriaceae (87% vs. 63%), but has a decreased sensitivity (92% vs. 100%) [Cohen Stuart 2011].
Confirmation – phenotypic

Several phenotypic methods based on the *in vitro* inhibition of ESBL activity by clavulanic acid are available for ESBL confirmation. However, three methods are recommended: 1) the combination disk diffusion test, 2) the Etest ESBL, or 3) broth microdilution ([Table 3]) [Drieux 2008, Jeong 2009, Paterson 2005]. However, the combination disk diffusion test showed a better specificity with comparable sensitivity, than the Etest ESBL [Platteel *unpublished data*].

The VITEK 2 ESBL confirmation test is not recommended for ESBL confirmation, based on the limited number of data and the diverging results that have been published [Leverstein-van Hall 2002, Spanu 2006, Thomson 2007]. It is recommended not to use the 'double disk approximation test', as its sensitivity is dependent on the optimal disk/tablet distance, and has been shown to be low in several studies [Bedenic 2007, Paterson 2005, Tzelepi 2000].

- **Combination disk diffusion test**
  
  A Mueller-Hinton agar or IsoSensitest agar plate is inoculated with a bacterial suspension of 0.5 McFarland according to the manufacturer’s instructions for use, and the cephalosporin disks/tablets are applied. The inhibition zone around the cephalosporin disk/tablet combined with clavulanic acid is compared to the zone around the disk/tablet with the cephalosporin alone. The test is positive if the inhibition zone is ≥ 5 mm larger with clavulanic acid than without (and the isolate has an MIC > 1 mg/L for the cephalosporin tested, i.e. ESBL screening is positive) ([Table 3]) [CLSI 2011, HPA 2008, M'Zali 2000]. In all other cases the test result is negative.

- **Antibiotic gradient on a strip method**
  
  A Mueller-Hinton agar or IsoSensitest agar plate is inoculated with a bacterial suspension of 0.5 McFarland, the Etest ESBL strip (AB Biodisk) is applied, and the strip is read according to the manufacturer’s instructions for use. The test is positive if a ≥ 8-fold reduction is observed in the MIC of the cephalosporin combined with clavulanic acid as compared to the MIC of the cephalosporin alone or if a deformation ellipse / phantom zone is present (and the isolate has an MIC > 1 mg/L of the cephalosporin tested, i.e. ESBL screening was positive) ([Table 3]). The test result is indeterminate if the strip cannot be read appropriately due to growth outside the range of the strip. In all other cases the test result is negative. The test is negative if the reduction in the MIC of the cephalosporin combined with clavulanic acid as compared to the MIC of the cephalosporin alone is less than 8-fold and/or if the Etest ESBL MIC of cefotaxime (or ceftriaxone) is < 0.5 mg/L and/or the Etest ESBL MIC of ceftazidime is < 1 mg/L (see manufacturer’s instructions). The Etest ESBL MIC should be used for confirmation of ESBL production only; it is not reliable for determination of the MIC.

- **Broth microdilution**
  
  Broth microdilution is performed with Mueller-Hinton broth containing serial twofold dilutions of cefotaxime (or ceftriaxone), ceftazidime and cefepime at concentrations ranging from 0.25 to 512 mg/L, with and without clavulanic acid at a fixed concentration of 4 mg/L. A bacterial suspension is inoculated into each well of the microtiter plate [Jeong 2009]. The microtiter plate is incubated at 37°C for 18 to 24 hours. The test is positive if a ≥ 8-fold reduction is observed in the MIC of the
cephalosporin combined with clavulanic acid as compared to the MIC of the cephalosporin alone. In all other cases the test result is negative [Jeong 2009].

Table 3. ESBL confirmation methods for Enterobacteriaceae that are positive in the ESBL screening (see Table 2)

<table>
<thead>
<tr>
<th>Group I Enterobacteriaceae (see Table 1)</th>
<th>Method</th>
<th>Antibiotic</th>
<th>Disk/tablet load</th>
<th>Confirmation is positive if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etest ESBL</td>
<td>Cefotaxime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8 or deformation ellipse</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8 or deformation ellipse / phantom zone present</td>
<td></td>
</tr>
<tr>
<td>Combination disk diffusion test</td>
<td>Cefotaxime +/- clavulanic acid</td>
<td>Cefotaxime 30 ug Clavulanic acid 10 ug</td>
<td>≥ 5 mm increase in inhibition zone²</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime +/- clavulanic acid</td>
<td>Ceftazidime 30 ug Clavulanic acid 10 ug</td>
<td>≥ 5 mm increase in inhibition zone²</td>
<td></td>
</tr>
<tr>
<td>Broth microdilution</td>
<td>Cefotaxime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ceftazidime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cefepime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Group II Enterobacteriaceae (see Table 1)</th>
<th>Method</th>
<th>Antibiotic</th>
<th>Screening is positive if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Etest ESBL</td>
<td>Cefepime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8 or deformation ellipse / phantom zone present</td>
</tr>
<tr>
<td>AB Biodisk</td>
<td>Cefepime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8 or deformation ellipse / phantom zone present</td>
</tr>
<tr>
<td>Combination disk diffusion test</td>
<td>Cefepime +/- clavulanic acid</td>
<td>Cefepime 30 ug Clavulanic acid 10 ug</td>
<td>≥ 5 mm increase in inhibition zone²</td>
</tr>
<tr>
<td>Broth microdilution</td>
<td>Cefepime +/- clavulanic acid</td>
<td>-</td>
<td>MIC ratio ≥ 8</td>
</tr>
</tbody>
</table>

ESBL = extended-spectrum beta-lactamase; MIC = minimal inhibitory concentration
1 MIC indicator cephalosporin / MIC indicator cephalosporin + clavulanic acid
2 Indicator cephalosporin + clavulanic acid compared with indicator cephalosporin alone

A. Phenotypic confirmation in group I Enterobacteriaceae

It is recommended to use both cefotaxime (or ceftriaxone) and ceftazidime for the confirmation of ESBL in group I Enterobacteriaceae (Table 3). Considering the varying affinity of the common classes of ESBL for cefotaxime and ceftazidime, synergy of clavulanic acid with at least one of these indicator cephalosporins is sufficient to confirm the presence of ESBL [CLSI 2011].

Indeterminate test results (Etest) and false-negative test results (combination disc diffusion test, Etest and broth microdilution) may result from the presence of AmpC beta-lactamases [Drieux 2008, Jacoby 2009, Munier 2010]. A cefoxitin MIC ≥ 16 mg/L is indicative for stable derepression of the AmpC beta-lactamase gene [Jacoby 2009]. Therefore, if test results for cefotaxime (or ceftriaxone) or ceftazidime are indeterminate (Etest) or when the isolate has a cefoxitin MIC ≥ 16 mg/L, it is recommended to perform an additional ESBL confirmation test using cefepime as indicator cephalosporin, as cefepime is not degraded by AmpC beta-lactamases [Drieux 2008]. In addition, indeterminate test results (Etest) may result from the presence of a carbapenemase gene [March 2010].
Other causes of false-negative test results are the presence of inhibitor-resistant class D (OXA) ESBLs [Naas 2008] or inhibitor-resistant TEM beta-lactamases [Sirot 1997].

ESBL confirmation tests that use cefotaxime as the indicator cephalosporin may be false-positive in *Klebsiella oxytoca* strains with hyperproduction of the chromosomal K1 beta-lactamase [Livermore 1995, Paterson 2005, Sanders 1996]. It is recommended to perform genotypic ESBL confirmation for *K. oxytoca* isolates that have a positive phenotypic ESBL confirmation test result.

Other, less common, causes of false-positive test results are hyperproduction of SHV-1 ESBLs in *Klebsiella pneumoniae* or the presence of class A carbapenemases (including KPC) [Nordmann 2009, Wu 2001].

### B. Phenotypic confirmation in group II Enterobacteriaceae

For group II Enterobacteriaceae it is recommended to perform ESBL confirmation tests with cefepime as the indicator cephalosporin (Table 3), as cefepime is not degraded by chromosomal AmpC beta-lactamases [Cohen Stuart 2011, Stürenburg 2004, Towne 2010]. Where the synergy between indicator cephalosporin and clavulanic acid may be masked in the presence of chromosomal AmpC beta-lactamases this will not occur when cefepime is used.

**Confirmation – genotypic**

For the genotypic confirmation of the presence of ESBL genes it is recommended to use PCR and ESBL gene sequencing [Bradford 2001] or a DNA microarray based method. The Check-KPC ESBL microarray (Check-Points) has recently been evaluated using different collections of selected ESBL-E containing the majority of known ESBL genes, and showed a good performance [Cohen Stuart 2010, Endimiani 2010, Naas 2010, Platteel 2011, Willemsen 2011]. Test results are obtained within 24 hours, which is more rapid than the phenotypic confirmation procedures. It should be noted that sporadically occurring ESBL and new ESBL genes are not detected by this microarray.

**Quality control**

The following strains are recommended for quality control: *K. pneumoniae* ATCC 700603 (ESBL-positive); and *E. coli* ATCC 25922 (ESBL-negative).

### 5.1.4 Contact tracing

#### 5.1.4.1 Adjusting diagnostic methods in case of a ‘known’ strain

The culture sites to be sampled, and the processing of the specimen are similar to those specified for the targeted screening for carriage of ESBL-E. For contact tracing it is recommended to use a (selective) medium that is optimised to detect the ‘known’ strain (see 5.1.3.2). It is essential to ensure that the ‘known’ strain grows in the medium that will be used for targeted screening.

#### 5.1.4.2 Molecular typing

It is recommended to compare ESBL-E isolates that are detected in contact patients to the isolate of the index patient by performing routine species identification and subsequent (geno)typing of strains.
Nosocomial transmission of ESBL may occur on different levels: 1) transmission of ESBL-producing strains, 2) transmission of plasmids encoding for ESBL, and 3) transmission of ESBL resistance genes. Typing methods that can be used to identify transmission of ESBL-E include amplified fragment length polymorphism (AFLP), pulsed field gel electrophoresis (PFGE), ribotyping and Raman spectroscopy. The analysis of potential transmission of plasmids and/or resistance genes goes beyond the scope of this guideline.

5.1.5 Reporting

5.1.5.1 Laboratory information system
ESBL confirmation test results should be reported in the laboratory information system as either ‘ESBL-positive’, ‘ESBL-negative’ or ‘ESBL-indeterminate’.

5.1.5.2 Patient information system
ESBL confirmation negative
The antibiogram to be reported in the patient information system should be in accordance with the MICs determined for the antimicrobial agents tested, without further adjustments.

ESBL confirmation positive
The antibiogram to be reported in the patient information system should be in accordance with the EUCAST clinical breakpoints [EUCAST 2011]. However, the working group takes the view that there is insufficient clinical evidence to support the treatment of infections with ESBL-E with non-carbapenem beta-lactam antibiotics. Thus, in case of an MIC below the clinical breakpoint for a beta-lactam antibiotic other than a carbapenem, it is recommended not to report the result for that particular antibiotic AND to provide a warning that it is unclear whether non-carbapenem beta-lactam antibiotics are effective in the treatment of serious infections caused by ESBL-E, and that treatment should be performed in consultation with a clinical microbiologist or an infectious diseases consultant.

ESBL confirmation indeterminate
The antibiogram to be reported in the patient information system should be in accordance with the EUCAST clinical breakpoints [EUCAST 2011]

5.1.6 Recommendations
Detection of carriage
• Feces or a rectal swab are the preferred specimens for the detection of carriage with HRE.
• Dependent on the clinical signs additional clinical sites should be sampled.
• A single set of cultures is sufficient for the targeted screening for carriage of HRE.
• Patients can be considered to be no longer carrying HRE if two culture sets, collected at least 24 hours apart, and at least 48 hours after discontinuation of antibiotic therapy are negative.
• Swabs should be collected in an adequate transport medium (Stuart or Amies). The use of dry swabs is not recommended.
• Clinical specimens should be processed within 24 hours after sampling, and kept at 4-8°C until processing.

Laboratory methods
• For targeted ESBL-E screening of clinical specimens an ESBL-E screening agar should be used.
• Routine identification methods for Enterobacteriacea are should be used, as there are no indications that the identification of Enterobacteriacea is different for susceptible or resistant isolates.
• Detection of ESBL in Enterobacteriacea should be a two-step procedure, consisting of a screening step followed by a confirmation step.
• Methods for ESBL screening in Enterobacteriacea are broth dilution, agar dilution, disk diffusion or an automated system.
• ESBL screening in Enterobacteriacea should be performed with both cefotaxime (or ceftriaxone) and ceftazidime as indicator cephalosporins.
• The screening breakpoint is > 1 mg/L for both cefotaxime (or ceftriaxone) and ceftazidime.
• Phenotypic methods for ESBL confirmation are the combination disk diffusion test, the Etest ESBL, or broth microdilution.
• Phenotypic ESBL confirmation in group I Enterobacteriacea should be performed with both cefotaxime (or ceftriaxone) and ceftazidime.
• In group I Enterobacteriacea an additional ESBL confirmation test with cefepime as indicator cephalosporin is needed if test results for cefotaxime (or ceftriaxone) or ceftazidime are indeterminate, or when the isolate has a cefoxitin MIC ≥ 16 mg/L.
• Phenotypic ESBL confirmation in group II Enterobacteriacea should be performed with cefepime.
• Genotypic ESBL confirmation should be performed for K. oxytoca isolates that have a positive phenotypic ESBL confirmation test result.
• Genotypic confirmation of the presence of ESBL genes can be performed by PCR and ESBL gene sequencing or a DNA microarray based method.
• The following strains are recommended for quality control: K. pneumoniae ATCC 700603 (ESBL-positive); and E. coli ATCC 25922 (ESBL-negative).

Contact tracing
• For contact tracing it is recommended to use a (selective) medium that is optimised to detect the ‘known’ strain.
• ESBL-E isolates that are detected in contact patients should be compared to the isolate of the index patient by performing routine species identification and subsequent (geno)typing of strains.

Reporting
• ESBL confirmation test results should be reported in the laboratory information system as either ‘ESBL-positive’, ‘ESBL-negative’ or ‘ESBL-indeterminate’.
• The antibiogram to be reported in the patient information system should be in accordance with the EUCAST clinical breakpoints. However, in case of an MIC below the clinical breakpoint for a beta-
lactam antibiotic other than a carbapenem, it is recommended not to report the result for that particular antibiotic AND to provide a warning that it is unclear whether non-carbapenem beta-lactam antibiotics are effective in the treatment of serious infections caused by ESBL-E, and that treatment should be performed in consultation with a clinical microbiologist or an infectious diseases consultant.
CHAPTER 5 - ENTEROBACTERIACEAE

5.3 Carbapenemases

Dr. J. Cohen Stuart, Dr. M.A. Leverstein – van Hall, Dr. N. al Naiemi

5.3.1 Introduction

The rapid emergence and dissemination of Enterobacteriaceae that are resistant to carbapenems, such as imipenem and meropenem, poses a considerable threat to clinical patient care and public health. Carbapenemase-producing Enterobacteriaceae (CPE) are characterised by their resistance to virtually all beta-lactam antibiotics, including the cephalosporins and carbapenems. In addition, many of these strains are also resistant to fluoroquinolones, aminoglycosides and co-trimoxazole [Bratu 2005, Souli 2010]. Invasive infections with these strains are associated with high rates of morbidity and mortality [Bratu 2005, Souli 2010].

The carbapenemases fall into three classes according to their amino acid sequence: Ambler class A (serine carbapenemases); class B (metallo-carbapenemases) and class D (OXA carbapenemases) [Queenan 2007]. Within these classes, further divisions are made, and new variants are frequently encountered [Queenan 2007]. The rapid emergence and spread of CPE is mainly caused by epidemics of bacteria bearing plasmid-mediated KPC (class A), VIM-1 and NDM (class B), and OXA-48 (class D) enzymes. Carbapenem minimum inhibitory concentrations (MICs) observed in CPE can exhibit considerable variation depending on the type and expression of carbapenemase enzyme, the bacterial species, and the presence of other resistance mechanisms such as cephalosporinases (ESBL and AmpC), reduced permeability and/or efflux pumps [Falcone 2009, Pasteran 2009, Tenover 2006]. Increased carbapenem MICs in Enterobacteriaceae may also result from high expression of AmpC or CTX-M ESBLs in combination with porin alterations [Pasteran 2009, Woodford 2007].

5.3.2 Detection of carriage

5.3.2.1 Culture sites

Feces or a rectal swab (visually contaminated) are the preferred specimens for the detection of carriage with highly resistant Enterobacteriaceae (HRE) [Paniagua 2010]. A perianal swab is slightly less sensitive, but is considered an acceptable non-invasive alternative to a rectal swab [Lautenbach 2005, Wiener-Well 2010]. A perineal swab is not recommended.

Dependent on the clinical signs and age the following additional sites should be sampled:

- Productive cough - sputum
- Intubation - sputum or aspirate
- Wound - wound swab
- Indwelling urinary catheter - urine
- Neonate - throat swab

5.3.2.2 Number of cultures

A single set of cultures is considered sufficient for the targeted screening for carriage of HRE.
Although repeated sampling may decrease the sample error, scientific data on this issue are currently insufficient to justify a recommendation to perform duplicate or repeated cultures. Once a patient has been identified as a carrier of HRE, it is not clear how many culture sets have to be taken to reliably identify loss of carriage of HRE. Therefore, the working group has decided to follow the current recommendations for the detection of carriage of *Salmonella* spp. [Behravesh 2008], i.e. patients can be considered to be no longer carrying HRE if two culture sets, collected at least 24 hours apart, and at least 48 hours after discontinuation of antibiotic therapy are negative. Since carriage of HRE may be prolonged, in particular in patients that are hospitalised and use antibiotics [Hart 1982, Yagci 2009], the working group takes the view that it is not appropriate to take such follow-up cultures during hospitalisation.

5.3.2.3 **Culture materials and transport**

Swabs should be collected in an adequate transport medium that maintains the viability of the microorganisms without permitting rapid multiplication during transport. Stuart transport medium or Amies transport medium are recommended. The use of dry swabs is not recommended, as this is associated with a reduced yield [Moore 2007]. Specimens should be processed within 24 hours after sampling, and kept at 4-8°C until processing.

5.3.3 **Laboratory methods**

5.3.3.1 **Direct molecular detection**

Standardised methods for the direct molecular detection of CPE in clinical samples are currently not available for routine use in medical microbiology laboratories.

5.3.3.2 **Solid agar media**

**Conventional media**

The detection of CPE from clinical specimens with non-selective conventional media may be hampered by overgrowth or the presence of populations with mixed susceptibilities.

**CPE screening agar**

For targeted CPE screening of clinical specimens it is recommended to use a CPE screening agar, as it allows for rapid detection and isolation of CPE. At present, two chromogenic agars for the detection of CPE with good performance are available in the Netherlands: CHROMagar KPC (Chromagar Microbiology), a selective agar for the detection of carbapenemases [Adler 2011, Panagea 2011, Moran Gilad 2011, Samra 2008], and the Brilliance CRE agar (Oxoid) [Cohen Stuart, unpublished data]. In addition, selective agars for the detection of ESBLs, such as chromID ESBL (bioMérieux) and Brilliance ESBL (Oxoid) [Carrër 2010, Nordmann 2011] may also be used to detect CPE, although there have been anecdotal reports of OXA-48 producing isolates that do not co-express ESBL [Carrër 2010].
5.3.3.3 **Broth enrichment**
Current published data do not provide sufficient evidence to recommend the use of an enrichment broth for the detection of CPE.

5.3.3.4 **Identification**
Current routine identification methods for Enterobacteriaceae should be used, as there are no indications that the identification of Enterobacteriaceae is different for susceptible or resistant isolates.

5.3.3.5 **Susceptibility testing**
The recommended strategy for the detection of carbapenemase production is a two-step procedure and consists of a screening step followed by a phenotypic and genotypic confirmation step (Figure 1). The screening step is based on the detection of reduced susceptibility to carbapenems in carbapenemase-producing isolates compared with isolates of the wild-type population. The phenotypic confirmation step is based on the detection of a diffusible carbapenemase and *in vitro* inhibition of carbapenemase activity upon addition of an inhibitor. The genotypic confirmation step consists of detection by polymerase chain reaction (PCR) and sequencing of carbapenemase genes.

**Screening**

**Screening breakpoints**
For each class of carbapenemases, and for each species and isolate, the MIC may vary from MICs of the wild-type population to > 256 mg/L, dependent on the presence of other resistance mechanisms. Setting of the recommended screening breakpoints has, therefore, been guided by the following principles: 1) the breakpoint MIC should be higher than the highest MIC of the wild-type population [EUCAST 2011], as the specificity of screening may otherwise become too low; and 2) the MIC breakpoint should be lower than the lowest carbapenem MICs described in the literature for strains shown to have a carbapenemase gene.

**Meropenem** - The recommended MIC screening breakpoint for meropenem has been set at > 0.25 mg/L for all Enterobacteriaceae, enabling the detection of the vast majority of carbapenemase-producers. Sporadic VIM-producers with meropenem MICs ≤ 0.25 mg/L and some OXA-48-producing isolates will not be detected using this breakpoint [Falcone 2009, Poirel 2011]. The recommended zone diameter screening breakpoint for meropenem has been set at < 24 mm. Although this zone diameter breakpoint was shown to be less sensitive than the MIC screening breakpoint of > 0.25 mg/L (84%-97% vs. 100%, respectively) [Cohen Stuart unpublished data, Pasteran 2009], it was shown to detect all VIM- and KPC-producing isolates [Vading 2011].

**Imipenem** - For imipenem it is not possible to set a breakpoint for all Enterobacteriaceae, as some species (*Proteus* spp., *Serratia* spp., *Providencia* spp. and *Morganella morganii*) have a high imipenem MIC owing to mechanisms other than carbapenemase production [EUCAST 2011]. However, for pragmatic reasons and based on the available wild-type MIC distributions, a screening breakpoint has been set for those species for which the MIC of imipenem can be used. For *E. coli*, *Klebsiella* spp., *Salmonella* spp., *Enterobacter* spp. and *Citrobacter* spp. the recommended imipenem
MIC screening breakpoint is > 1 mg/L, and the zone diameter screening breakpoint is < 22 mm. Although the recommended imipenem MIC screening breakpoint of > 1 mg/L was shown to have a sensitivity of 79% [Pasteran 2009], the breakpoint was not set lower because the MIC distribution of the wild-type population is up to 1 mg/L [EUCAST 2011]. It has been shown that the sensitivity of the imipenem zone diameter screening breakpoint of < 22 mm was 100% [Pasteran 2009, Vading 2011].

**Ertapenem** - Ertapenem is not advised as an indicator carbapenem in this guideline, since it has a lower specificity than imipenem and meropenem. Ertapenem is less specific because isolates with AmpC/ESBL and decreased permeability have higher MICs for ertapenem than for imipenem or meropenem [Cohen Stuart unpublished data, Woodford 2007]. However, in case of an outbreak with OXA-48 producing Enterobacteriaceae, it is recommended to use an ertapenem screening breakpoint of > 0.25 mg/L. OXA-48 producing Enterobacteriaceae may have a meropenem MIC ≤ 0.25 mg/L, whereas ertapenem MICs for these isolates are > 0.25 mg/L [Poirel 2011].

**In conclusion** - Carbapenemase screening in Enterobacteriaceae should be performed with both meropenem and imipenem. Routine screening with ertapenem is not recommended, but should be used in case of an outbreak with OXA-48 producing microorganisms.

**Methods**

Carbapenemase screening should be a standard component of the susceptibility testing on all Enterobacteriaceae isolated in routine diagnostics. This can take place by assessing the carbapenem MICs or by an alert from the expert system. When using automated systems for susceptibility testing (e.g. Phoenix, VITEK, or MicroScan), antibiotic panels containing both meropenem and imipenem are preferred. The preferred lowest concentration in the panels is 0.25 mg/L for meropenem, and 1 mg/L for imipenem. The laboratory should be aware that strains with an MIC above the carbapenemase screening breakpoint but below the clinical breakpoint might nevertheless have a carbapenemase gene. Thus, strains with a meropenem MIC of 0.5 mg/L, 1 mg/L or 2 mg/L or an imipenem MIC of 2 mg/L are susceptible according to EUCAST clinical breakpoints, but should still be tested for the presence of a carbapenemase gene.

To exclude technical errors and to limit the number of strains to be confirmed for carbapenemase production, a carbapenem MIC above the screening breakpoint measured by an automated system, should be confirmed by an antibiotic gradient on a strip method (e.g. Etest) with meropenem or imipenem on Mueller-Hinton agar (MHA) [Cohen Stuart 2010]. It is recommended not to use Iso-Sensitest agar as the carbapenem MICs of metallo-carbapenemase producers may be underestimated due to the low zinc concentrations [Walsh 2002]. Determining the MIC of carbapenemase-positive strains with an Etest can be complicated because mutant colonies with higher MICs than the dominant population may be found in the inhibition ellipse. These colonies should be included when interpreting the Etest, in accordance with the manufacturers’ instructions.
Confirmation – phenotypic

On the first isolate per species from a patient with a positive carbapenemase screen test, a PCR-based test should be performed to confirm the presence of carbapenemase genes (Figure 1). However, if genotypic confirmation is not immediately available, phenotypic confirmation tests can be performed in order to avoid delayed reporting of potential carbapenemase-producers to the clinic. Phenotypic confirmation can be performed using the modified Hodge test and/or the carbapenemase inhibition tests [Miriagou 2010, Pasteran 2009, Pasteran 2010].

Modified Hodge test

The modified Hodge test (Figure 2) is based on the detection of diffusible carbapenemases. It should be performed according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [CLSI 2010]. The modified Hodge test has a high sensitivity (95-100%) [Miriagou 2010, Pasteran 2009]. In addition, it is the only phenotypic confirmation test that is positive in case of OXA-48.

BA = boronic acid derivative; DPA = dipicolinic acid; EDTA = ethylenediaminetetraacetic acid; MIC = minimal inhibitory concentration

1 The zone diameter screening breakpoint for meropenem has been set at < 24 mm with a disc content of 10 ug. For Escherichia coli, Klebsiella spp. and Enterobacter spp. the zone diameter screening breakpoint for imipenem has been set at < 22 mm with a disc content of 10 ug.
imipenem

Inhibition of *E.coli* ATCC 25922

Production. Disadvantages of this test are the subjectivity and difficulty with test interpretation and the fact that different classes of carbapenemases cannot be distinguished. The specificity may be low because CTX-M ESBL- or AmpC beta-lactamase producing isolates with reduced or absent porin expression may give false-positive results [Pasteran 2009, Pasteran 2010] (Table 2). However, for the detection of class A carbapenemases the specificity of the modified Hodge test can be increased by performing the double modified Hodge test [Pasteran 2010].

Figure 2. Modified Hodge test

Meropenem

Ertapenem

Carbapenemase inhibition tests (synergy tests)

The carbapenemase inhibition tests are based on the *in vitro* inhibition of carbapenemase activity by addition of an inhibitor that is specific for a class of carbapenemases (resulting in a reduction in the MIC of the carbapenem). This phenomenon is called synergy between the carbapenem and the inhibitor. Carbapenemase inhibition tests can be used to distinguish between the different classes of carbapenemases (Table 1 and Table 2). For the detection of class A carbapenemases boronic acid (BA) derivatives are used as the inhibitor. To exclude AmpC as the cause of carbapenem resistance, an inhibition test with cloxacillin should be added to the boronic acid inhibition tests. For the detection of class B carbapenemases, ethylenediaminetetraacetic acid (EDTA) or dipicolinic acid (DPA) can be used as an inhibitor.

It is recommended to use either combination disk diffusion tests or an antibiotic gradient on a strip method (e.g. Etest) with the strip containing both meropenem and an inhibitor. Table 1 shows the details of the combination tests as recommended by a group of experts from EUCAST and the ESCMID Study Group for Antibiotic Resistance Surveillance (ESGARS) [Miriagou 2010], as well as how these should be interpreted. Test characteristics and validation reports of the inhibition tests for the routine setting, only some of which are commercially available, are limited [Giske 2011, Tsakris 2010]. Double disk synergy tests (disk approximation methods) are not recommended, since the
sensitivity depends on the optimal distance between the disks, which cannot be predicted [Bedenic 2007, Paterson 2005, Tzelepi 2000].

Table 1. Phenotypic confirmation methods for class A and class B carbapenemases

<table>
<thead>
<tr>
<th>Carbapenemase</th>
<th>Method</th>
<th>Antibiotic</th>
<th>Disc/tablet load</th>
<th>Inoculum Medium</th>
<th>Confirmation is positive if</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class A</td>
<td>Combination diffusion - tablet</td>
<td>Meropenem +/- APBA</td>
<td>Meropenem 10 ug APBA</td>
<td>0.5 McF MHA</td>
<td>≥ 5 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td></td>
<td>Combination diffusion - disc in-house</td>
<td>Meropenem +/- APBA</td>
<td>Meropenem 10 ug APBA 600 ug</td>
<td>0.5 McF MHA</td>
<td>≥ 4 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td></td>
<td>Combination diffusion - disc in-house</td>
<td>Meropenem +/- PBA</td>
<td>Meropenem 10 ug PBA 400 ug</td>
<td>0.5 McF MHA</td>
<td>≥ 4 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td>Class B</td>
<td>Combination diffusion - disc in-house</td>
<td>Meropenem +/- EDTA</td>
<td>Meropenem 10 ug EDTA 292 ug</td>
<td>0.5 McF MHA</td>
<td>≥ 5 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td></td>
<td>Combination diffusion - disc in-house</td>
<td>Meropenem +/- EDTA</td>
<td>Meropenem 10 ug EDTA 730 ug</td>
<td>0.5 McF MHA</td>
<td>≥ 5 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td></td>
<td>Combination diffusion - tablet Rosco</td>
<td>Meropenem +/- DPA</td>
<td>Meropenem 10 ug DPA 1000 ug</td>
<td>0.5 McF MHA</td>
<td>≥ 5 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td></td>
<td>Combination diffusion - tablet in-house</td>
<td>Meropenem +/- DPA</td>
<td>Meropenem 10 ug DPA 1000 ug</td>
<td>0.5 McF MHA</td>
<td>≥ 5 mm increase in inhibition zone¹</td>
</tr>
<tr>
<td></td>
<td>Etest MBL</td>
<td>Imipenem +/- EDTA</td>
<td>-</td>
<td>0.5 McF MHA</td>
<td>MIC ratio² ≥ 8 or phantom zone present or deformation of ellipse⁴</td>
</tr>
</tbody>
</table>

APBA = 3-aminophenylboronic acid; DPA = dicolonic acid; EDTA = ethylenediaminetetraacetic acid; MBL = metallo-beta-lactamase; McF = McFarland standards; MHA = Mueller-Hinton agar; MIC = minimal inhibitory concentration; PBA = phenylboronic acid

1 Carbenapenem + inhibitor compared with carbapenem alone
2 The brand of the MHA may influence the test characteristics of class B carbapenemase inhibition tests that use EDTA as inhibitor [Walsh 2002].
3 MIC imipenem / MIC imipenem + EDTA
4 To avoid false-negative results, the result of the MBL Etest should be interpreted as indeterminate if the MIC for imipenem < 4 mg/L AND the MIC for imipenem + EDTA < 1 mg/L.

References: [Giske 2011, Tsakris 2010]

Table 2. Interpretation of phenotypic carbapenemase confirmation test results

<table>
<thead>
<tr>
<th>Confirmation test</th>
<th>Class of carbapenemase</th>
<th>AmpC beta-lactamase with reduced permeability</th>
<th>ESBL with reduced permeability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified Hodge test</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meropenem / imipenem</td>
<td>+</td>
<td>+</td>
<td>+/-</td>
</tr>
<tr>
<td>Carbapenemase inhibition tests</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meropenem +/- APBA</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Meropenem +/- PBA</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Meropenem +/- DPA</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Meropenem +/- cloxacillin</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
</tr>
<tr>
<td>Meropenem +/- EDTA</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

APBA = 3-aminophenylboronic acid; DPA = dicolonic acid; EDTA = ethylenediaminetetraacetic acid; ESBL = extended-spectrum beta-lactamase; PBA = phenylboronic acid
Confirmation – genotypic
Genotypic confirmation comprises PCR detection and sequencing of carbapenemase genes. Alternatively, a microarray (e.g. Check-Points) may be used to detect the most prevalent carbapenemase genes (OXA-48, KPC, VIM, NDM and IMP) [Naas 2011]. The high diversity of genes with ever-increasing numbers of new variants implies that isolates with a negative genotypic result in the local laboratory setting should be sent to a reference laboratory for further genotypic confirmation. Currently, the following carbapenemase genes can be detected by PCR and sequencing: class A: KPC, SME, NMC-A, IMI, PER, GES, SFO, SFC, IBC; class B: VIM, GIM, SIM, NDM, IMP, SPM; and class D: OXA, PSE [Dallenne 2010, Voets 2011].

Quality control
The following strains are recommended for quality control: E. coli ATCC 25922 (carbapenemase-negative); K. pneumoniae ATCC BAA-1705 (KPC-positive); and K. pneumoniae ATCC BAA-1706 (carbapenem-resistant due to other mechanisms than carbapenemase; modified Hodge test-negative).

5.3.4 Contact tracing
5.3.4.1 Adjusting diagnostic methods in case of a ‘known’ strain
The culture sites to be sampled, and the processing of the specimen are similar to those specified for the targeted screening for carriage of CPE. For contact tracing it is recommended to use a (selective) medium that is optimised to detect the ‘known’ strain (see 5.3.3.2). It is essential to ensure that the ‘known’ strain grows in the medium that will be used for targeted screening.

5.3.4.2 Molecular typing
It is recommended to compare CPE isolates that are detected in contact patients to the isolate of the index patient by performing routine species identification and subsequent (geno)typing of strains. Nosocomial transmission of carbapenemase resistance may occur on different levels: 1) transmission of carbapenemase-producing strains, 2) transmission of plasmids encoding for carbapenem resistance, and 3) transmission of carbapenem resistance genes. Typing methods that can be used to identify transmission of carbapenemase-producing strains include amplified fragment length polymorphism (AFLP), pulsed field gel electrophoresis (PFGE), ribotyping and Raman spectroscopy. The analysis of potential transmission of plasmids and/or resistance genes goes beyond the scope of this guideline.

5.3.5 Reporting
5.3.5.1 Laboratory information system
Genotypic carbapenemase confirmation test results should be reported in the laboratory information system as either ‘carbapenemase-positive’, or ‘carbapenemase-negative’.
5.3.5.2 Patient information system

CPE confirmation negative
The antibiogram to be reported in the patient information system should be in accordance with the MICs determined for the antimicrobial agents tested, without further adjustments.

CPE confirmation positive
The antibiogram to be reported in the patient information system should be in accordance with the EUCAST clinical breakpoints [EUCAST 2011]. However, the working group takes the view that there is insufficient clinical evidence to support the treatment of infections with CPE with beta-lactam antibiotics. Thus, in case of an MIC below the clinical breakpoint for a beta-lactam antibiotic, it is recommended not to report the result for that particular antibiotic AND to provide a warning that it is unclear whether beta-lactam antibiotics are effective in the treatment of serious infections caused by CPE, and that treatment should be performed in consultation with a clinical microbiologist or an infectious diseases consultant.

5.3.6 Recommendations

Detection of carriage
• Feces or a rectal swab are the preferred specimens for the detection of carriage with HRE.
• Dependent on the clinical signs additional clinical sites should be sampled.
• A single set of cultures is sufficient for the targeted screening for carriage of HRE.
• Patients can be considered to be no longer carrying HRE if two culture sets, collected at least 24 hours apart, and at least 48 hours after discontinuation of antibiotic therapy are negative.
• Swabs should be collected in an adequate transport medium (Stuart or Amies). The use of dry swabs is not recommended.
• Clinical specimens should be processed within 24 hours after sampling, and kept at 4-8°C until processing.

Laboratory methods
• For targeted CPE screening of clinical specimens a CPE screening agar should be used. An ESBL-E screening agar may also be used, although OXA-48 producing isolates that do not produce ESBL cannot be detected.
• Routine identification methods for Enterobacteriaceae should be used, as there are no indications that the identification of Enterobacteriaceae is different for susceptible or resistant isolates.
• Detection of carbapenemase production in Enterobacteriaceae should be a two-step procedure, consisting of a screening step followed by a phenotypic and genotypic confirmation step.
• Carbapenemase screening in Enterobacteriaceae should be performed with both meropenem and imipenem. Routine screening with ertapenem is not recommended, but should be used in case of an outbreak with OXA-48 producing microorganisms.
• For all Enterobacteriaceae the MIC screening breakpoint for meropenem is > 0.25 mg/L, and the zone diameter screening breakpoint is < 24 mm.
• For *E. coli*, *Klebsiella* spp., *Salmonella* spp., *Enterobacter* spp., and *Citrobacter* spp. the MIC screening breakpoint for imipenem is > 1 mg/L, and the zone diameter screening breakpoint is < 22 mm.

• A carbapenem MIC above the screening breakpoint measured by an automated system should be confirmed with an antibiotic gradient on a strip method (e.g. Etest) on MHA (not on Iso-Sensitest).

• On the first isolate per species from a patient with a positive carbapenemase screen test, a PCR-based test should be performed to confirm the presence of carbapenemase genes.

• Phenotypic methods for CPE confirmation are the modified Hodge test and carbapenemase inhibition tests.

• The following strains are recommended for quality control: *E. coli* ATCC 25922 (carbapenemase-negative); *K. pneumoniae* ATCC BAA-1705 (KPC-positive); and *K. pneumoniae* ATCC BAA-1706 (carbapenem-resistant due to other mechanisms than carbapenemase; modified Hodge test-negative).

**Contact tracing**

• For contact tracing it is recommended to use a (selective) medium that is optimised to detect the ‘known’ strain.

• CPE isolates that are detected in contact patients should be compared to the isolate of the index patient by performing routine species identification and subsequent (geno)typing of strains.

**Reporting**

• Genotypic carbapenemase confirmation test results should be reported in the laboratory information system as either ‘carbapenemase-positive’, or ‘carbapenemase-negative’.

• The antibiogram to be reported in the patient information system should be in accordance with the EUCAST clinical breakpoints. However, in case of an MIC below the clinical breakpoint for a beta-lactam antibiotic, it is recommended not to report the result for that particular antibiotic AND to provide a warning that it is unclear whether beta-lactam antibiotics are effective in the treatment of serious infections caused by CPE, and that treatment should be performed in consultation with a clinical microbiologist or an infectious diseases consultant.